{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T20:31:41Z","timestamp":1787085101785,"version":"build-2736575974"},"reference-count":90,"publisher":"Begell House","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Crit Rev Immunol"],"published-print":{"date-parts":[[2026]]},"abstract":"<p>Despite major advances in antiretroviral therapy (ART), a definitive cure for human immunodeficiency virus (HIV) remains elusive. This review aims to propose a unified, multidimensional framework for HIV cure that integrates virologic, immunologic, and clinical perspectives to guide future research and therapeutic strategies. A structured narrative review was conducted using PubMed, Scopus, Web of Science, and Google Scholar to identify relevant literature on HIV cure research. Articles published primarily between 2008 and 2026 were screened based on relevance, scientific rigor, and contribution to key themes. Findings were synthesized qualitatively to provide an integrated overview of emerging concepts, persistent challenges, and future directions in HIV cure research. Effective HIV cure strategies must integrate three interconnected dimensions: (1) virologic cure through durable suppression or elimination of replication-competent virus, (2) clinical cure through sustained remission without antiretroviral therapy (ART), and (3) immunologic cure through restoration of functional immune competence and inflammatory homeostasis. Current and emerging approaches, including latency-targeting agents, broadly neutralizing antibodies, therapeutic vaccines, immune modulators, and gene-editing technologies, demonstrate potential to bridge viral suppression with immune-mediated control. However, critical challenges persist, including reservoir heterogeneity, immune senescence, viral diversity, and the absence of standardized immunologic metrics. Proposed endpoints extend beyond CD4&lt;sup&gt;&amp;#43;&lt;\/sup&gt; T cell counts to functional T cell responses, immune memory restoration, and normalization of inflammatory profiles. An effective HIV cure must integrate viral suppression, immune restoration, and functional remission. This unified, multidimensional framework provides a foundation for next-generation therapeutic strategies and clinical trial design aimed at achieving durable, host-mediated control.<\/p>","DOI":"10.1615\/critrevimmunol.2026064384","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T20:57:31Z","timestamp":1779829051000},"page":"57-78","source":"Crossref","is-referenced-by-count":0,"title":["Toward a Unified Multidimensional HIV Cure: Integrating Virologic, Clinical, and Immunologic Perspectives"],"prefix":"10.1615","volume":"46","author":[{"given":"Seyi Samson","family":"Enitan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chukwudi Amaechi","family":"Ofodile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard Yomi","family":"Akele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayodeji Olusola","family":"Olayanju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Okeoghene Marcel","family":"Edafetanure-Ibeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Eleojo","family":"Itodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinedu-madu Jane","family":"Ugochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nnaji Joseph","family":"Chima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chukwuma J.","family":"Okafor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Comfort Bosede","family":"Enitan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roselene Nmesoma","family":"Odimgbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"613","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Lackner AA, Lederman MM, Rodriguez B. HIV pathogenesis: The host. Cold Spring Harb Perspect Med. 2012;2(9):a007005.","DOI":"10.1101\/cshperspect.a007005"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Yang T, Yang X, Li L, Xu H, Fan L, Li Q, Fan X, Chen W, Du X, Hao C, Li J. HIV diagnosis period influences ART initiation: Findings from a prospective cohort study in China. AIDS Res Ther. 2021;18(1):59.","DOI":"10.1186\/s12981-021-00379-3"},{"key":"3","unstructured":"World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva, Switzerland: WHO; 2016. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK374318\/."},{"key":"4","unstructured":"World Health Organization. Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. Geneva, Switzerland: WHO; 2021. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK569321\/."},{"key":"5","doi-asserted-by":"crossref","unstructured":"Looney D, Ma A, Johns S. HIV therapy\u2014The state of the art. Curr Top Microbiol Immunol. 2015;389:1\u201329.","DOI":"10.1007\/82_2015_440"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Eshun-Wilson I, Awotiwon AA, Germann A, Amankwaa SA, Ford N, Schwartz S, Baral S, Geng EH. Effects of community-based antiretroviral therapy initiation models on HIV treatment outcomes: A systematic review and meta-analysis. PLoS Med. 2021;18(5):e1003646.","DOI":"10.1371\/journal.pmed.1003646"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Simonetti FR, Kearney MF. Influence of ART on HIV genetics. Curr Opin HIV AIDS. 2015;10(1):49\u201354.","DOI":"10.1097\/COH.0000000000000120"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Wang H, Lu X. Editorial: HIV\/AIDS: Pathogenesis and vaccine. Front Cell Infect Microbiol. 2025;15:1584301.","DOI":"10.3389\/fcimb.2025.1584301"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Iwuji CC, McGrath N, de Oliveira T, Porter K, Pillay D, Fisher M, Newport M, Newell ML. The art of HIV elimination: Past and present science. J AIDS Clin Res. 2015;6:525.","DOI":"10.4172\/2155-6113.1000525"},{"key":"10","unstructured":"Radix AE, Vail RM, Shah SS, Fine SM, McGowan JP, Merrick ST, Monroe AK, Rodrigues J, Hoffmann CJ, Norton BL, Gonzalez CJ. Rapid ART initiation. In: HIV clinical guidelines. Baltimore, MD: Johns Hopkins University; 2025. Available from: https:\/\/www.ncbi.nlm.nih. gov\/books\/ NBK557123\/."},{"key":"11","doi-asserted-by":"crossref","unstructured":"Peluso MJ, Sandel DA, Deitchman AN, Kim SJ, Dalhuisen T, Tummala HP, Tib\u00farcio R, Zemelko L, Borgo GM, Singh SS, Schwartz K. Correlates of HIV-1 control after combination immunotherapy. Nature. 2026;650(8100):187\u201395.","DOI":"10.1038\/s41586-025-09929-5"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Shepherd RA, Tanaka K, King HA, Schou MD, Williams OH, Kim Y, Roche M, Lewin SR. Host-directed approaches in the pursuit of a cure for HIV. Antiviral Res. 2025;240:106216.","DOI":"10.1016\/j.antiviral.2025.106216"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Mao Q, Li L, Wen H. Beyond monotherapy: Combination therapies for HIV-1 cure through joint application of neutralizing antibodies, genome editing, and reservoir management. Infect Med. 2025;4(4):100215.","DOI":"10.1016\/j.imj.2025.100215"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Talla A, Azevedo JL, Latif MB, Enriquez AB, Sanchez GP, Pelletier AN, Bal SK, Kumari S, Schuch V, Ghneim K, Rhodes A. Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy. Nat Med. 2026;32:505\u201317. doi: 10.1038\/s41591-025-04139-y","DOI":"10.1038\/s41591-025-04139-y"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Xu W, Li H, Wang Q, Hua C, Zhang H, Li W, Jiang S, Lu L. Advancements in developing strategies for sterilizing and functional HIV cures. BioMed Res Int. 2017;2017(1):6096134. doi: 10.1155\/2017\/6096134","DOI":"10.1155\/2017\/6096134"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Tolomeo M, Cascio A. Block-and-lock approaches for HIV cure: Mechanistic insights, challenges, and emerging role of CPSF6. Int J Mol Sci. 2026;27(8):3496.","DOI":"10.3390\/ijms27083496"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Davenport MP, Khoury DS, Cromer D, Lewin SR, Kelleher AD, Kent SJ. Functional cure of HIV: The scale of the challenge. Nat Rev Immunol. 2019;19(1):45\u201354.","DOI":"10.1038\/s41577-018-0085-4"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Dub\u00e9 K, Willenberg L, Dee L, Sylla L, Taylor J, Roebuck C, Palm D, Campbell D, Newton L, Patel H, Perry KE. Re-examining the HIV \u2018functional cure\u2019oxymoron: Time for precise terminology? J Virus Erad. 2020;6(4):100017.","DOI":"10.1016\/j.jve.2020.100017"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Sardo L, Parolin C, Yoshida T, Garzino-Demo A, Izumi T. Editorial: Novel insights into a functional HIV cure. Front Microbiol. 2021;12:797570.","DOI":"10.3389\/fmicb.2021.797570"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Papadopoulos AO, Moodley M, Mendoza CA, Ndhlovu ZM. CD8+ T cell immunity in HIV cure and prevention: Linking stemness, spatial niches, and emerging therapeutic strategies. Annu Rev Immunol. 2026;44(1):95\u2013120.","DOI":"10.1146\/annurev-immunol-082724-125809"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Ward AR, Mota TM, Jones RB. Immunological approaches to HIV cure. Semin Immunol. 2021;51:101412.","DOI":"10.1016\/j.smim.2020.101412"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Moran JA, Turner SR, Marsden MD. Contribution of sex differences to HIV immunology, pathogenesis, and cure approaches. Front Immunol. 2022;13:905773.","DOI":"10.3389\/fimmu.2022.905773"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Chen H, Moussa M, Catalfamo M. The role of immunomodulatory receptors in the pathogenesis of HIV infection: A therapeutic opportunity for HIV cure? Front Immunol. 2020;11:1223.","DOI":"10.3389\/fimmu.2020.01223"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Board NL, Moskovljevic M, Wu F, Siliciano RF, Siliciano JD. Engaging innate immunity in HIV-1 cure strategies. Nat Rev Immunol. 2022;22(8):499\u2013512.","DOI":"10.1038\/s41577-021-00649-1"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Garc\u00eda F. \u2018Functional cure\u2019 of HIV infection: The role of immunotherapy. Immunotherapy. 2012;4(3):245\u20138.","DOI":"10.2217\/imt.12.2"},{"key":"26","unstructured":"Spach DH. HIV 101: Fundamentals of HIV Infection. In: Topics in antiviral medicine. 2018. Available from: https:\/\/www.iasusa.org\/wp-content\/uploads\/2018\/rwcc\/esyllabus\/01-rwcc18-hiv101-spach.pdf."},{"key":"27","unstructured":"Spach DH, Wood BR. Antiretroviral medications and initial therapy. 2018. Available from: https:\/\/www.hiv.uw.edu\/go\/antiretroviral-therapy\/general-information\/core-concept\/all"},{"key":"28","unstructured":"Saag MS. HIV 101: Fundamentals of antiretroviral therapy. In: Topics in antiviral medicine. San Francisco, CA: International Antiviral Society-USA (IAS-USA); 2019. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6892619\/."},{"key":"29","unstructured":"Alcam\u00ed J. The HIV replication cycle: Established therapeutic targets and potential targets. Enferm Infecc Microbiol Clin. 2008;26 Suppl 12:3\u201310."},{"key":"30","doi-asserted-by":"crossref","unstructured":"Ferguson MR, Rojo DR, von Lindern JJ, O\u2019Brien WA. HIV-1 replication cycle. Clin Lab Med. 2002;22(3):611\u201335.","DOI":"10.1016\/S0272-2712(02)00015-X"},{"key":"31","doi-asserted-by":"crossref","unstructured":"T\u00f6zs\u00e9r J. Stages of HIV replication and targets for therapeutic intervention. Curr Top Med Chem. 2003;3(13):1447\u201357.","DOI":"10.2174\/1568026033451781"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Adamson CS, Freed EO. Novel approaches to inhibiting HIV-1 replication. Antiviral Res. 2010;85(1):119\u201341.","DOI":"10.1016\/j.antiviral.2009.09.009"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Nuwagaba J, Li JA, Ngo B, Sutton RE. 30 years of HIV therapy: Current and future antiviral drug targets. Virology. 2025;603:110362.","DOI":"10.1016\/j.virol.2024.110362"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Li S, Moog C, Zhang T, Su B. HIV reservoir: Antiviral immune responses and immune interventions for curing HIV infection. Chin Med J. 2022;135(22):2667\u201376.","DOI":"10.1097\/CM9.0000000000002479"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Chou TC, Maggirwar NS, Marsden MD. HIV persistence, latency, and cure approaches: Where are we now? Viruses. 2024;16(7):1163.","DOI":"10.3390\/v16071163"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Macias J, Palomares JC, Mira JA, Torres MJ, Garc\u00eda-Garc\u00eda JA, Rodr\u00edquez JM, Vergera S, Pineda JA. Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J Infect. 2005;51(3):195\u2013200.","DOI":"10.1016\/j.jinf.2004.11.010"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Jones LE, Perelson AS. Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;45(5):483\u201393.","DOI":"10.1097\/QAI.0b013e3180654836"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Martinez-Picado J, Deeks SG. Persistent HIV-1 replication during antiretroviral therapy. Curr Opin HIV AIDS. 2016;11(4):417\u201323.","DOI":"10.1097\/COH.0000000000000287"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Barton K, Winckelmann A, Palmer S. HIV-1 reservoirs during suppressive therapy. Trends Microbiol. 2016;24(5):345\u201355.","DOI":"10.1016\/j.tim.2016.01.006"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Mzingwane ML, Tiemessen CT. Mechanisms of HIV persistence in HIV reservoirs. Rev Med Virol. 2017;27(2):e1924.","DOI":"10.1002\/rmv.1924"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Kimata JT, Rice AP, Wang J. Challenges and strategies for the eradication of the HIV reservoir. Curr Opin Immunol. 2016;42:65\u201370.","DOI":"10.1016\/j.coi.2016.05.015"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Zhang C, Chaudhary BN, Ali MU, Heser MG, Patel SS, Du X, Dey SS, Mosley RL, Panja S, Gendelman HE. Searching for a HIV-1 Cure. Theranostics. 2026;16(5):2170.","DOI":"10.7150\/thno.124358"},{"key":"43","unstructured":"Mostafa M. Human immunodeficiency virus: Emerging modalities in treatment. Andijan Region, Uzbekistan: Shokh Articles Library; Worldly Knowledge Publishing House; 2026. Available from: https:\/\/worldsiencepub.com\/index.php\/shokhal\/article\/view\/4391\/4213."},{"key":"44","doi-asserted-by":"crossref","unstructured":"Schriek AI, Aldon YL, van Gils MJ, de Taeye SW. Next generation broadly neutralizing antibodies for HIV 1 cure strategies. Antiviral Res. 2024;222:105788.","DOI":"10.1016\/j.antiviral.2023.105788"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Lee J, Whitney JB. Immune checkpoint inhibition as a therapeutic strategy for HIV eradication: Current insights and future directions. Curr Opin HIV AIDS. 2024;19(4):179\u201386.","DOI":"10.1097\/COH.0000000000000863"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Van Zandt AR, MacLean AG. Advances in HIV therapeutics and cure strategies: Findings obtained through non human primate studies. J Neurovirol. 2023;29(4):389\u201399.","DOI":"10.1007\/s13365-023-01162-y"},{"key":"47","doi-asserted-by":"crossref","unstructured":"Padurariu-Covit MD, Georgescu C, Andreescu M, Chiscop I, Plesea-Condratovici C, Arbune M. CAR-T cell therapy for HIV cure: Current challenges, advances and future directions. Viruses. 2025;17(12):1615.","DOI":"10.3390\/v17121615"},{"key":"48","unstructured":"Gramatica, A. How T cells are defining the future of HIV therapies and beyond. amfAR. 2025. Available from: https:\/\/www.amfar.org\/news\/how-t-cells-are-defining-the-future-of-hiv-therapies-and-beyond\/."},{"key":"49","doi-asserted-by":"crossref","unstructured":"Leibman RS, Riley JL. Engineering T cells to functionally cure HIV-1 infection. Mol Ther. 2015;23(7):1149\u201359.","DOI":"10.1038\/mt.2015.70"},{"key":"50","doi-asserted-by":"crossref","unstructured":"Mu W, Carrillo MA, Kitchen SG. Engineering CAR T Cells to target the HIV reservoir. Front Cell Infect Microbiol. 2020;10:410.","DOI":"10.3389\/fcimb.2020.00410"},{"key":"51","doi-asserted-by":"crossref","unstructured":"Matsui Y, Miura Y. Advancements in cell-based therapies for HIV cure. Cells. 2024;13(1):64.","DOI":"10.3390\/cells13010064"},{"key":"52","doi-asserted-by":"crossref","unstructured":"Qi J, Ding C, Jiang X, Gao Y. Advances in developing CAR T-cell therapy for HIV cure. Front Immunol. 2020;11:361.","DOI":"10.3389\/fimmu.2020.00361"},{"key":"53","doi-asserted-by":"crossref","unstructured":"Xiao Q, He S, Wang C, Zhou Y, Zeng C, Liu J, Liu T, Li T, Quan X, Wang L, Zhai L. Deep thought on the HIV cured cases: Where have we been and what lies ahead? Biomolecules. 2025;15(3):378.","DOI":"10.3390\/biom15030378"},{"key":"54","doi-asserted-by":"crossref","unstructured":"Lindegger DJ. Advanced therapies for human immunodeficiency virus. Med Sci. 2024;12(3):33.","DOI":"10.3390\/medsci12030033"},{"key":"55","doi-asserted-by":"crossref","unstructured":"Wu F, Simonetti FR. Learning from persistent viremia: Mechanisms and implications for clinical care and HIV 1 cure. Curr HIV\/AIDS Rep. 2023;20(6):428\u201339.","DOI":"10.1007\/s11904-023-00674-w"},{"key":"56","doi-asserted-by":"crossref","unstructured":"McLaren PJ, Fellay J. HIV 1 and human genetic variation. Nat Rev Genet. 2021;22(10):645\u201357.","DOI":"10.1038\/s41576-021-00378-0"},{"key":"57","doi-asserted-by":"crossref","unstructured":"Santoro MM, Perno CF. HIV 1 genetic variability and clinical implications. Adv Virol. 2013;2013:481314.","DOI":"10.1155\/2013\/481314"},{"key":"58","doi-asserted-by":"crossref","unstructured":"Zhou S, Long N, Swanstrom R. Evolution driven by a varying host environment selects for distinct HIV 1 entry phenotypes and other informative variants. Front Virol. 2023:3:1291996.","DOI":"10.3389\/fviro.2023.1291996"},{"key":"59","doi-asserted-by":"crossref","unstructured":"Langford SE, Ananworanich J, Cooper DA. Predictors of disease progression in HIV infection: A review. AIDS Res Ther. 2007;4:11.","DOI":"10.1186\/1742-6405-4-11"},{"key":"60","doi-asserted-by":"crossref","unstructured":"Easterbrook PJ, Smith M, Mullen J, O\u2019Shea S, Chrystie I, de Ruiter A, Tatt ID, Geretti AM, Zuckerman M. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc. 2010;13(1):4.","DOI":"10.1186\/1758-2652-13-4"},{"key":"61","doi-asserted-by":"crossref","unstructured":"Ogbenna AA, Meloni S, Inzaule S, Hamers RL, Sigaloff K, Osibogun A, Adeyemo TA, Okonkwo P, Samuels JO, Kanki PJ, Rinke de Wit TF. The impact of HIV-1 subtypes on virologic and immunologic treatment outcomes at the Lagos University Teaching Hospital: A longitudinal evaluation. PLoS One. 2020;15(8):e0238027.","DOI":"10.1371\/journal.pone.0238027"},{"key":"62","doi-asserted-by":"crossref","unstructured":"El Bouzidi K, Datir RP, Kwaghe V, Roy S, Frampton D, Breuer J, Ogbanufe O, Murtala-Ibrahim F, Charurat M, Dakum P, Sabin CA. Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria. J Antimicrob Chemother. 2022;77(2):474\u201382.","DOI":"10.1093\/jac\/dkab385"},{"key":"63","doi-asserted-by":"crossref","unstructured":"He J, Wei Y, Shi Y, Yang M, Chen H, Dai J, Wang J, Jin X, Zeng Z, Sun P, Fu L. HIV-1 genetic diversity and pretreatment drug resistance in Xishuangbanna, a China-Myanmar-Laos border region. BMC Infect Dis. 2026;26:633.","DOI":"10.1186\/s12879-026-12865-y"},{"key":"64","doi-asserted-by":"crossref","unstructured":"Orlova-Morozova E, Kireev D, Kirichenko A, Bobkov V, Antonova A, Yapparov R, Bobkova M. Real-world efficacy of bictegravir\/emtricitabine\/tenofovir alafenamide regimen in patients infected with HIV-1 sub-subtype A6 harbouring the L74I mutation. HIV Med. 2025;26(9): 1463\u20137.","DOI":"10.1111\/hiv.70073"},{"key":"65","unstructured":"den Uyl D, van der Horst-Bruinsma IE, van Agtmael M. Progression of HIV to AIDS: A protective role for HLA-B27? AIDS Rev. 2004;6(2):89\u201396."},{"key":"66","doi-asserted-by":"crossref","unstructured":"Hiremath PM, Suri D, Arora K, Shandilya J, Rawat A, Singh S. Human leukocyte antigen B27 and B57 alleles in HIV-infected long-term nonprogressor children. AIDS. 2021;35(4):703\u20135.","DOI":"10.1097\/QAD.0000000000002770"},{"key":"67","doi-asserted-by":"crossref","unstructured":"Lobos CA, Downing J, D\u2019Orsogna LJ, Chatzileontiadou DSM, Gras S. Protective HLA-B57: T cell and natural killer cell recognition in HIV infection. Biochem Soc Trans. 2022;50(5):1329\u201339.","DOI":"10.1042\/BST20220244"},{"key":"68","doi-asserted-by":"crossref","unstructured":"Zubair A, Bibi B, Alkahtani AM, Shahani MY, Afghan N. World free HIV: The novel therapeutic approaches for eliminating latent HIV infection. Virol J. 2026;23(1):52.","DOI":"10.1186\/s12985-026-03089-2"},{"key":"69","doi-asserted-by":"crossref","unstructured":"Matsuda K, Maeda K. HIV reservoirs and treatment strategies toward curing HIV infection. Int J Mol Sci. 2024;25(5):2621.","DOI":"10.3390\/ijms25052621"},{"key":"70","doi-asserted-by":"crossref","unstructured":"Borrajo A. Breaking barriers to an HIV-1 cure: Innovations in gene editing, immune modulation, and reservoir eradication. Life. 2025;15(2):276.","DOI":"10.3390\/life15020276"},{"key":"71","doi-asserted-by":"crossref","unstructured":"Restrepo Arenas V, Rugeles MT, Perdomo-Celis F, Taborda N. Recent advances in CD8+ T cell-based immune therapies for HIV cure. Heliyon. 2023;9(6):e17481.","DOI":"10.1016\/j.heliyon.2023.e17481"},{"key":"72","doi-asserted-by":"crossref","unstructured":"Su H, Mueller A, Goldstein H. Recent advances on anti-HIV chimeric antigen receptor T cell treatment to provide sustained HIV remission. Curr Opin HIV AIDS. 2024;19(4):169\u201378.","DOI":"10.1097\/COH.0000000000000858"},{"key":"73","doi-asserted-by":"crossref","unstructured":"Pitman MC, Lau JS, McMahon JH, Lewin SR. Barriers and strategies to achieve a cure for HIV. Lancet HIV. 2018;5(6):e317\u201328.","DOI":"10.1016\/S2352-3018(18)30039-0"},{"key":"74","doi-asserted-by":"crossref","unstructured":"Mbhele N, Chimukangara B, Tyers L, Maldarelli F, Redd AD. Advancements in single-cell techniques for examining the HIV reservoir: Pathways to a cure. Mbio. 2025;16(7):e0065525.","DOI":"10.1128\/mbio.00655-25"},{"key":"75","doi-asserted-by":"crossref","unstructured":"Zhang X, Chen J. HIV reservoir: How to measure it? Curr HIV\/AIDS Rep. 2023;20(2):29\u201341.","DOI":"10.1007\/s11904-023-00653-1"},{"key":"76","doi-asserted-by":"crossref","unstructured":"Abdel-Mohsen M, Richman D, Siliciano RF, Nussenzweig MC, Howell BJ, Martinez-Picado J, Chomont N, Bar KJ, Yu XG, Lichterfeld M, Alcami J. Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nat Med. 2020;26(9):1339\u201350.","DOI":"10.1038\/s41591-020-1022-1"},{"key":"77","doi-asserted-by":"crossref","unstructured":"Wang Z, Simonetti FR, Siliciano RF, Laird GM. Measuring replication competent HIV-1: Advances and challenges in defining the latent reservoir. Retrovirology. 2018;15(1):21.","DOI":"10.1186\/s12977-018-0404-7"},{"key":"78","doi-asserted-by":"crossref","unstructured":"Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: Implications for curative approaches to HIV infection. Immunol Rev. 2013;254(1):326\u201342.","DOI":"10.1111\/imr.12065"},{"key":"79","doi-asserted-by":"crossref","unstructured":"Rehman SU. Revolutionizing hiv\/aids treatment: Advances in crispr\/cas9. Braz J Pharm Sci. 2026;62:e24485.","DOI":"10.1590\/s2175-97902026e24485"},{"key":"80","doi-asserted-by":"crossref","unstructured":"Reddy K, Reddy N, Ndung\u2019u T. The implications of HIV-1 subtypes on pathogenesis, reservoirs and cure strategies. Curr HIV\/AIDS Rep. 2026;23(1):11.","DOI":"10.1007\/s11904-026-00780-5"},{"key":"81","doi-asserted-by":"crossref","unstructured":"Lau JS, Lewin SR, Telwatte S. HIV and the gut: Implications for HIV persistence, immune dysfunction and cure strategies. Front Immunol. 2025;16:1650852.","DOI":"10.3389\/fimmu.2025.1650852"},{"key":"82","doi-asserted-by":"crossref","unstructured":"Brown E. Can we realize a functional cure of HIV? Science Insights. 2026;48(2):2137\u201340.","DOI":"10.15354\/si.26.op117"},{"key":"83","doi-asserted-by":"crossref","unstructured":"Pasternak AO, Berkhout B. HIV persistence: Silence or resistance? Curr Opin Virol. 2023;59:101301.","DOI":"10.1016\/j.coviro.2023.101301"},{"key":"84","unstructured":"Quinn SL. On single-cell immune dynamics of chronic HIV infection and treatment in rhesus macaque models [dissertation].Boston: Massachusetts Institute of Technology; 2025. Available from: https:\/\/dspace.mit.edu\/entities\/publication\/013e213a-3831-45ae-b1ae-43bfb95de4a2."},{"key":"85","unstructured":"Presti R, Kennedy W, Craddick TJ, Gordon J. First-in-Human study of EBT-101 in aviremic HIV-1 infected adults on stable ART. In: Proceedings of the 27th Annual Meeting of the American Society of Gene & Cell Therapy (pp. 7\u201311); Baltimore, MD, USA; May 10, 2024. Available from: https:\/\/www.researchgate.net\/profile\/William_Kennedy8\/publication\/381734557_First-in-Human_Study_of_EBT-101_in_Aviremic_HIV-1_Infected_Adults_on_Stable_ART\/links\/667c9f22714e0b03152c0e27\/First-in-Human-Study-of-EBT-101-in-Aviremic-HIV-1-Infected-Adults-on-Stable-ART.pdf."},{"key":"86","doi-asserted-by":"crossref","unstructured":"Vasconcelos Komninakis S, Domingues W, Saeed Sanabani S, Angelo Folgosi V, Neves Barbosa I, Casseb J. CRISPR\/CAS as a powerful tool for human immunodeficiency virus cure: A review. AIDS Res Hum Retroviruses. 2024;40(6): 363\u201375.","DOI":"10.1089\/aid.2022.0148"},{"key":"87","doi-asserted-by":"crossref","unstructured":"Moso MA, Roche M, Cevaal PM, Lewin SR. CRISPR\/Cas9 for achieving postintervention HIV control. Curr Opin HIV AIDS. 2025;20(5):432\u201340.","DOI":"10.1097\/COH.0000000000000963"},{"key":"88","doi-asserted-by":"crossref","unstructured":"Wang CX, Cannon PM. The clinical applications of genome editing in HIV. Blood. 2016;127(21):2546\u201352.","DOI":"10.1182\/blood-2016-01-678144"},{"key":"89","doi-asserted-by":"crossref","unstructured":"Lewin SR, Bansbach C, Kemps D, Mathae L, Das KT, McCune JM, Deeks SG, Ndung\u2019u T. Target product profile for cell-based and gene-based therapies to achieve a cure for HIV. Lancet HIV. 2025;12(2):e154\u201362.","DOI":"10.1016\/S2352-3018(24)00277-7"},{"key":"90","doi-asserted-by":"crossref","unstructured":"Kibibi Wairimu H. Emerging CRISPR-based therapeutics for HIV eradication. Res Invent J Publ Health Pharm. 2024;3(3):10\u20135.","DOI":"10.59298\/RIJPP\/2024\/331015"}],"container-title":["Critical Reviews in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/1b526d4969b35ddd\/CRI-64384.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T20:10:54Z","timestamp":1787083854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/2ff21abf44b19838,74b10211737d60bd,1b526d4969b35ddd.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1615\/critrevimmunol.2026064384","relation":{},"ISSN":["1040-8401"],"issn-type":[{"value":"1040-8401","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}